Stay Ahead of Compliance with Monthly Citation Updates


In your State Survey window and need a snapshot of your risks?

Survey Preparedness Report

One Time Fee
$79
  • Last 12 months of citation data in one tailored report
  • Pinpoint the tags driving penalties in facilities like yours
  • Jump to regulations and pathways used by surveyors
  • Access to your report within 2 hours of purchase
  • Easily share it with your team - no registration needed
Get Your Report Now →

Monthly citation updates straight to your inbox for ongoing preparation?

Monthly Citation Reports

$18.90 per month
  • Latest citation updates delivered monthly to your email
  • Citations organized by compliance areas
  • Shared automatically with your team, by area
  • Customizable for your state(s) of interest
  • Direct links to CMS documentation relevant parts
Learn more →

Save Hours of Work with AI-Powered Plan of Correction Writer


One-Time Fee

$49 per Plan of Correction
Volume discounts available – save up to 20%
  • Quickly search for approved POC from other facilities
  • Instant access
  • Intuitive interface
  • No recurring fees
  • Save hours of work
F0605
D

Failure to Monitor Psychotropic Medication Use and Indications

York, Pennsylvania Survey Completed on 05-22-2025

Penalty

No penalty information released
tooltip icon
The penalty, as released by CMS, applies to the entire inspection this citation is part of, covering all citations and f-tags issued, not just this specific f-tag. For the complete original report, please refer to the 'Details' section.

Summary

The facility failed to ensure adequate monitoring for the use of psychotropic medications for two residents. For one resident with diabetes mellitus type 2 and hypertension, there was an active order for Seroquel, an antipsychotic medication, but the clinical record lacked evidence of side effect monitoring or behavior monitoring to track the targeted behaviors for which the medication was prescribed. The Director of Nursing confirmed that neither side effect nor behavior monitoring was in place for this resident. For another resident admitted with dementia and adjustment disorder with mixed anxiety and depressed mood, there was an order for Risperdal, an antipsychotic, initially documented for anxiety/agitation/combative behaviors. The order was later revised to indicate schizophrenia, despite no supporting documentation of this diagnosis in the clinical record. There was no evidence of identified behaviors, ongoing behavior monitoring, or side effect monitoring for the use of Risperdal. A pharmacist's recommendation requested clarification of the medication's indication, and the DON confirmed that the order had been corrected and that appropriate monitoring should have been initiated when the medication was first ordered.

An unhandled error has occurred. Reload 🗙